Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

  • Webcast Image Webcast
    X Cytokinetics 2018 R&D Day
    Oct 16, 2018 8:30 AM EDT

    Cytokinetics 2018 R&D Day
    Oct 16, 2018 8:30 AM EDT
  • Webcast Image Webcast
    X Q3 2018 Cytokinetics, Inc. Earnings Conference Call
    Nov 1, 2018 4:30 PM EDT

    Q3 2018 Cytokinetics, Inc. Earnings Conference Call
    Nov 1, 2018 4:30 PM EDT
  • Webcast Image Webcast
    X Cytokinetics, Inc. at the Credit Suisse 27th Annual Healthcare Conference
    Nov 13, 2018 10:20 AM MST

    Cytokinetics, Inc. at the Credit Suisse 27th Annual Healthcare Conference
    Nov 13, 2018 10:20 AM MST
  • Webcast Image Webcast
    X Cytokinetics, Inc. at the 30th Annual Piper Jaffray Healthcare Conference
    Nov 27, 2018 10:00 AM EST

    Cytokinetics, Inc. at the 30th Annual Piper Jaffray Healthcare Conference
    Nov 27, 2018 10:00 AM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

07/13/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND
Baseline Characteristics and Demographics from FORTITUDE-ALS Similar to Other Recent Large Trials in ALS SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29 th International Symposium on
Toggle Summary Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor
SOUTH SAN FRANCISCO, Calif. , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK-3773274 (CK-274)
Toggle Summary Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
Clinical Trial Results Expected First Half 2019 SOUTH SAN FRANCISCO, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS ( F unctional O utcomes in a R andomized T rial of I nvestigational T
Toggle Summary Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced five poster presentations at the 29 th International Symposium on ALS/MND in Glasgow, Scotland , UK . The posters will be presented on Friday, December 7, 2018 and Saturday, December 8,

EVENTS

There are currently no events to display.